The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype

Satu Tiainen1,2 · Kirsi Rilla3 · Kirsi Hämäläinen4,5,6 · Sanna Oikari3 · Päivi Auvinen1,2

Purpose The aim of this study was to investigate the prognostic impact of two systemic inflammatory markers, the neutrophil-to-lymphocyte ratio (NLR) and the monocyte-to-lymphocyte ratio (MLR), and their possible predictive role regarding the efficacy of adjuvant trastuzumab, in 209 early breast cancer cases, 107 of which were HER2-positive.

Methods Baseline NLR and MLR values were divided into two groups, high and low, according to cut-off-points determined from the ROC curve (2.2 for NLR and 0.22 for MLR). Cox’s model was utilized for survival analyses.

Results High NLR and MLR correlated with poor overall survival (OS) and breast cancer specific survival (BCSS) among all the patients (p ≤ 0.030). Among the HER2+ patients whose adjuvant treatment did not include trastuzumab (n = 64), the survival rates were remarkably lower in patients with a high NLR as compared to those with low; 31% vs. 71% for OS and 42% vs. 74% for BCSS (p ≤ 0.014). Similarly, high MLR correlated with poor survival among these patients (p ≤ 0.020). On the contrary, among the patients who had received adjuvant trastuzumab (n = 43), NLR or MLR did not correlate with survival. Furthermore, trastuzumab was beneficial for the HER2+ patients with high NLR/MLR, while the survival of the HER2+ patients with low NLR/MLR was good irrespective if they received adjuvant trastuzumab.

Conclusions Our results suggest that trastuzumab modulates the systemic inflammatory conditions and overcomes the poor prognostic impact of high NLR/MLR. This finding may also provide a rationale for combining trastuzumab with immunoncological treatments in HER2+ breast cancer.

Keywords Breast cancer · NLR · MLR · Trastuzumab · HER2

Introduction

Systemic inflammatory state of the host and the inflammatory response in the tumor microenvironment have a remarkable impact on cancer progression [1, 2]. Neutrophils secrete cytokines that promote cancer growth [3], and they may also suppress the immune responses mediated by lymphocytes [4]. Furthermore, monocytes are able to suppress lymphocyte activation and enhance tumor progression [5]. On the other hand, lymphocytes have an important role in the immune responses against cancer both in the circulation and in the tumor microenvironment, e.g., via T-cell mediated cellular cytotoxicity [6]. Therefore, the blood...
Indeed, high levels of tumor infiltrating lymphocytes (TILs) can be considered as indicators of the host’s systemic inflammatory state [7], i.e., high NLR and MLR may reflect poor anti-tumor immunity. Several studies have investigated the prognostic role of NLR in breast cancer (BC) [7]. In two rather recent meta-analyses, a high NLR was shown to predict poor overall survival (OS) and disease free survival (DFS) among BC patients [8, 9]. The associations were evident especially among those patients with hormone receptor (HR) negative and/or human epidermal growth factor receptor 2 (HER2) negative BC but less clear among the HER2+ patients [8, 9]. The impact of MLR on BC prognosis has been less extensively studied. Some publications suggest that a high MLR associates with a poor outcome in BC [7, 10] but there are also studies reporting no correlation between MLR and BC outcome [7, 11].

One of the major advances in the treatment of BC has been the development of trastuzumab, a HER2 antibody, which has remarkably improved the outcome of HER2+ patients [12]. A part of trastuzumab’s anti-tumor effects are mediated via the immune system, especially through antibody-dependent cellular cytotoxicity (ADCC) [6]. First, trastuzumab binds to the surface of cancer cells and activates the innate immune response, resulting in the death of cancer cells by macrophages and natural killer (NK) cells. Dying cancer cells release trastuzumab-coated antigens, which activate cytotoxic T-lymphocytes leading to an adaptive immune response and death of the cancer cells presenting this antigen [6]. Indeed, high levels of tumor infiltrating lymphocytes (TILs) have been shown to associate with a better response to trastuzumab in HER2+ BC [13]. There are only a few studies investigating the possible predictive role of the blood inflammatory cells in HER2+ BC treated with trastuzumab, and the results have been conflicting [14–16].

The aim of this study was to investigate the prognostic impact of both NLR and MLR in a material of 209 BC patients, 107 of them HER2+. Patients were diagnosed between 2001 and 2008 and 40% of the HER2+ patients had received adjuvant trastuzumab, since adjuvant trastuzumab only became widely available in Finland in 2005. Thus, this material provides a rather unique opportunity to investigate also if these two markers of systemic inflammation, NLR and MLR, have a predictive role regarding the efficacy of adjuvant trastuzumab treatment.

Material and methods

Patient material

The primary patient material included 278 BC cases diagnosed in Kuopio University Hospital between 2001–2008; first all HER2+ operated cases with adequate tissue blocks (n = 139) were included and then the same number of HER2− cases matched for the time of operation and age were selected [17]. The information of the complete blood count with white blood cell (WBC) differential was available for 209 eligible patients (107 HER2+ and 102 HER2−), which is the number of patients included in the present study. Clinicopathological data including the information of adjuvant treatments, laboratory tests and survival were collected manually from the patient records of Kuopio University Hospital. The conduction of this study was in accordance with the Declaration of Helsinki, and the ethical approval was provided by the Ethics Committee of the University of Eastern Finland (February 24, 2009, 19//2009).

Laboratory tests

The complete blood count with WBC differential was determined from the blood samples in the laboratory of Kuopio University Hospital with an Advia 120 Hematology System (Bayer Diagnostics Co., Tarrytown, NY, USA). Blood samples taken within 3 months after BC surgery and before the initiation of adjuvant treatments were included but blood samples taken during an infection were excluded. The ratios between the WBC counts were calculated as follows; NLR = neutrophils divided by lymphocytes and MLR = monocytes divided by lymphocytes. In the statistical analyses, the NLR and MLR values were each graded as low or high according to optimal cut-off-points determined from the receiver operating characteristic (ROC) curve.

Immunohistochemistry and in situ hybridization

HER2 expression (chromogenic in situ hybridization test) and other standard histopathogenic parameters, e.g., tumor size, nodal status, grade, histological type and HR status (immunohistochemistry) were determined according to international guidelines [18] in Kuopio University Hospital, Department of Pathology at the time of diagnosis. The cut-off points for estrogen receptor (ER) and progesterone receptor (PR) positivity were 10% according to the guidelines at the time of diagnosis, and cases were defined as HR+ when either ER or PR was positive.

Statistical analyses

IBM SPSS Statistics version 25 (IBM Corporation, Armonk, NY, USA) was utilized for the statistical analyses. The optimal cut-off points for NLR and MLR were determined from the ROC curve. Chi-square test was used for calculating the differences between the investigated factors, Cox’s model for survival analyses and the Kaplan Meier method for plotting the survival curves. OS and BC specific survival (BCSS)
were determined as the time from diagnosis to the date of death or end of follow-up; for OS death from any cause was counted as an event, and death from BC for BCSS. The survival rates were calculated at the end of the follow-up time. In the Cox’s multivariate survival analyses the factors included were NLR, MLR, tumor size (T2-4 vs. T1), nodal status (N1-3 vs N0), HR and HER2 status, and for HER2+ subgroup also adjuvant trastuzumab. p-values ≤ 0.05 were regarded as statistically significant.

Results

The WBC differential was available for 209 eligible patients (107 HER2+ and 102 HER2−) and the demographics of these cases are presented in Table 1. The median follow-up time was 10.4 years (range 0.5–15.2). Median age was 58.1 years (range 32.3–82.7) and 35% of the patients were premenopausal (Table 1). Deaths and breast cancer relapses occurred more often among the HER2+ patients than among the HER2− patients (p ≤ 0.006) (Table 1). Median time from the BC surgery to the blood sample collection was 6.0 weeks (range 0.3–12.8). The optimal cut-off-points calculated with the ROC curve were 2.2 for NLR (AUC 0.624, 95% CI 0.54–0.71, p = 0.006) and 0.22 for MLR (AUC 0.597, 95% CI 0.51–0.68, p = 0.031). High NLR (≥ 2.2) was found in 35% and high MLR (≥ 0.22) in 43% of the patients (Table 1). In the HER2+ subgroup, a high NLR was found in 38% and a high MLR in 42% of the patients; the corresponding values in the HER2− subgroup were 31% for high NLR and 43% for high MLR (Table 1). Similarly, in the HR+ subgroup (n = 150), a high NLR was found in 35% and a high MLR in 41% of the patients, and the corresponding values in the HR− subgroup (n = 59) were 34% for high NLR and 46% for high MLR. There were no correlations between NLR or MLR and standard prognostic factors, i.e., tumor size, nodal status, grade, HER2 or HR status (data not shown).

High NLR and MLR correlate with poor OS and BCSS

Among all the patients (n = 209), the OS rate at the end of the follow-up was worse in patients with a high NLR as compared to those with a low NLR, 60% vs. 79% (p = 0.004), and similarly the BCSS rates were 71% vs. 85% (p = 0.023) for high and low NLR, respectively (Table 2). A high MLR also correlated with poor survival as the OS rate was 61% vs. 82% (p = 0.001) and the BCSS rate 73% vs. 85% (p = 0.030) for high and low MLR, respectively (Table 2). In the HR+ subgroup (n = 150), high NLR and MLR correlated with poor OS (p ≤ 0.044), as well as in the HR− subgroup (n = 59) (p ≤ 0.044) (Table 2). The distributions of the standard prognostic histopathological parameters were similar in NLR/MLR high and low groups among all the patients and in the HR+ and HR− subgroups (data not shown). There were only 14 patients with triple-negative BC and no correlations were found between NLR or MLR and survival (Table 2).

Among the HER2+ patients (n = 107), OS was inferior in patients with a high NLR as compared to those with a low NLR, 46% vs. 73% (p = 0.011), and BCSS showed a similar trend, 59% vs. 74%, respectively (p = 0.084) (Table 2). Similarly, the OS and BCSS rates were 47% vs. 74% (p = 0.005) and 58% vs. 76% (p = 0.040) for patients with high and low MLR, respectively (Table 2). In addition, 41.5% (17/41) and 44% (20/45) of the patients with high NLR or MLR, respectively, suffered a distant relapse during the follow-up as compared to the corresponding values of 29% (19/66) of patients with low NLR and 26% (16/62) with low MLR (p = 0.177 and p = 0.044, respectively). Among the HER2− patients (n = 102) there were no statistically significant differences

| Table 1 Demographics of the cases |
|----------------------------------|
|                                | All (n = 209) | HER2+ (n = 107) | HER2− (n = 102) |
|----------------------------------|---------------|----------------|-----------------|
| T1                               | 124 (59)      | 57 (53)        | 67 (66)         |
| T2                               | 70 (34)       | 42 (39)        | 28 (27)         |
| T3                               | 5 (2)         | 3 (3)          | 2 (2)           |
| T4                               | 10 (5)        | 5 (5)          | 5 (5)           |
| N0                               | 78 (37)       | 35 (33)        | 43 (42)         |
| N1                               | 96 (46)       | 46 (43)        | 50 (49)         |
| N2                               | 25 (12)       | 17 (16)        | 8 (8)           |
| N3                               | 10 (5)        | 9 (8)          | 1 (1)           |
| Grade 1                          | 20 (9)        | 4 (4)          | 16 (16)         |
| Grade 2                          | 95 (46)       | 38 (35)        | 57 (56)         |
| Grade 3                          | 94 (45)       | 65 (61)        | 29 (28)         |
| Ductal                           | 170 (81)      | 91 (85)        | 79 (77)         |
| Lobular                          | 22 (11)       | 8 (7.5)        | 14 (14)         |
| Other                            | 17 (8)        | 8 (7.5)        | 9 (9)           |
| HR positive                      | 150 (72)      | 62 (58)        | 88 (86)         |
| HR negative                      | 59 (28)       | 45 (42)        | 14 (14)         |
| Prenenopausal                    | 74 (35)       | 37 (35)        | 37 (36)         |
| Postmenopausal                   | 135 (65)      | 70 (65)        | 65 (64)         |
| Any death                        | 57 (27)       | 40 (37)        | 17 (17)         |
| Death due to BC                  | 42 (20)       | 34 (32)        | 8 (8)           |
| BC any relapse                   | 64 (31)       | 42 (39)        | 22 (22)         |
| BC distant relapse               | 50 (24)       | 36 (34)        | 14 (14)         |
| NLR low                          | 136 (65)      | 66 (62)        | 70 (69)         |
| NLR high                         | 73 (35)       | 41 (38)        | 32 (31)         |
| MLR low                          | 120 (57)      | 62 (58)        | 58 (57)         |
| MLR high                         | 89 (43)       | 45 (42)        | 44 (43)         |

T tumor classification, N nodal classification, HR hormone receptor, BC breast cancer, NLR neutrophil-to-lymphocyte ratio, MLR monocyte-to-lymphocyte ratio
in OS, BCSS (Table 2) or recurrence rates (data not shown) according to either NLR or MLR. There were no significant differences in the distributions of the standard histopathological factors in NLR/MLR high and low groups among the HER2+ or HER2− patients (data not shown).

**High NLR and MLR correlate with poor survival among HER2+ patients only if not treated with adjuvant trastuzumab**

Of the HER2+ patients, 82% had received chemotherapy, 53% hormonal therapy and 95% radiation therapy among adjuvant treatments (Table 3). Also, 40% (43/107) had received adjuvant trastuzumab but 60% (64/107) had not since they were treated before adjuvant trastuzumab was included in the national and international guidelines (Table 3). All the patients treated with adjuvant

### Table 2 OS and BCSS rates at the end of the follow-up according to NLR and MLR values

|          | OS p value | HR 95% CI | BCSS p value | HR 95% CI |
|----------|------------|-----------|--------------|-----------|
| All (n = 209) |            |           |              |           |
| NLR high | 60%        | 0.004     | 2.13         | 1.27–3.58 | 71% 0.023 | 2.02         | 1.10–3.70   |
| NLR low  | 79%        |           |              |           | 85%         |
| MLR high | 61%        | 0.001     | 2.41         | 1.41–4.12 | 73% 0.030 | 1.97         | 1.07–3.64   |
| MLR low  | 82%        |           |              |           | 85%         |
| HER2+ (n = 107) |          |           |              |           |
| NLR high | 46%        | 0.011     | 2.25         | 1.21–4.21 | 59% 0.084 | 1.81         | 0.92–3.55   |
| NLR low  | 73%        |           |              |           | 74%         |
| MLR high | 47%        | 0.005     | 2.46         | 1.30–4.63 | 58% 0.040 | 2.04         | 1.04–4.01   |
| MLR low  | 74%        |           |              |           | 76%         |
| HER2− (n = 102) |        |           |              |           |
| NLR high | 78%        | 0.393     | 1.52         | 0.58–4.01 | 88% 0.293 | 2.11         | 0.53–8.42   |
| NLR low  | 86%        |           |              |           | 94%         |
| MLR high | 75%        | 0.053     | 2.68         | 0.99–7.28 | 89% 0.232 | 2.40         | 0.57–10.06  |
| MLR low  | 90%        |           |              |           | 95%         |
| HR+ (n = 150) |         |           |              |           |
| NLR high | 70%        | 0.044     | 2.06         | 1.02–4.18 | 79% 0.059 | 2.33         | 0.97–5.64   |
| NLR low  | 85%        |           |              |           | 91%         |
| MLR high | 69%        | 0.014     | 2.47         | 1.20–5.10 | 82% 0.157 | 1.89         | 0.78–4.57   |
| MLR low  | 86%        |           |              |           | 90%         |
| HR− (n = 59) |         |           |              |           |
| NLR high | 35%        | 0.023     | 2.44         | 1.13–5.28 | 50% 0.118 | 1.96         | 0.84–4.53   |
| NLR low  | 67%        |           |              |           | 69%         |
| MLR high | 41%        | 0.044     | 2.25         | 1.02–4.97 | 52% 0.120 | 1.96         | 0.84–4.59   |
| MLR low  | 69%        |           |              |           | 72%         |
| TNBC (n = 14) |        |           |              |           |
| NLR high | 50%        | 0.294     | 2.86         | 0.40–20.35 | 75% 0.758 | 1.46         | 0.13–16.15  |
| NLR low  | 80%        |           |              |           | 80%         |
| MLR high | 67%        | 0.876     | 1.17         | 0.16–8.32 | 83% 0.655 | 0.58         | 0.05–6.40   |
| MLR low  | 75%        |           |              |           | 75%         |

*OS* overall survival, *BCSS* breast cancer specific survival, *NLR* neutrophil-to-lymphocyte ratio, *MLR* monocyte-to-lymphocyte ratio, *HR* hazard ratio, *CI* confidence interval, *HR+* hormone receptor positive, *TNBC* triple-negative breast cancer, *HR−* hormone receptor negative

### Table 3 Adjuvant treatments of the HER2+ patients

|                  | HER2+ (n = 107) n (%) |
|------------------|----------------------|
| Any chemo        | 88 (82)              |
| Anthracycline    | 68 (64)              |
| Taxane           | 40 (37)              |
| Any trastuzumab  | 43 (40)              |
| Trastuzumab with taxane | 30 (28)       |
| Trastuzumab with vinorelbine | 6 (6)       |
| Trastuzumab after chemo | 7 (6.5)    |
| Hormonal therapy | 57 (53)              |
| Radiation therapy| 102 (95)             |

*Chemo* chemotherapy
trastuzumab received also chemotherapy, of them 93% (40/43) anthracycline and 81% (35/43) taxane. Of the HER2+ patients who did not receive trastuzumab, chemotherapy was administered to 70% (45/64) and the regimen included anthracycline in 44% (28/64) and taxane in only 8% (5/64) of the cases. Otherwise the adjuvant treatments and the standard histopathological factors distributed similarly (data not shown). Of the patients treated with trastuzumab, 74% (32/43) had received a short duration adjuvant trastuzumab, i.e., three doses together with chemotherapy, while 26% (11/43) had received trastuzumab for 1 year.

Among the HER2+ patients whose adjuvant treatment did not include trastuzumab, the outcome of the patients with a high NLR was poor. As presented in Fig. 1 and Table 4, the OS rate at the end of the follow-up was only 31% among the patients with a high NLR as compared to 71% among the patients with a low NLR (p = 0.003) (Fig. 1a, Table 4). In addition, the BCSS rate was clearly lower in patients with a high NLR as compared to those with a low NLR, 42% vs. 74% (p = 0.014), respectively (Fig. 1b, Table 4). Similarly, a high MLR correlated with poor OS and BCSS among these patients (p ≤ 0.020) (Fig. 1c, d, Table 4). Furthermore, distant relapses were more frequent among the patients with either high NLR or MLR in comparison to those with low values, 58% (15/26) vs. 32% (12/38) (p = 0.038) for NLR, and 59% (16/27) vs. 30% (11/37) (p = 0.018) for MLR. The standard histopathological factors distributed similarly in the NLR/MLR high and low groups (Supplementary Table S1). Surprisingly, among the HER2+ patients who had received adjuvant trastuzumab, there were no differences in OS or BCSS according to either NLR or MLR (Fig. 1e–h, Table 4). The trastuzumab treated groups were otherwise in balance, but the frequency of T1 tumors was higher in the NLR high group than in the NLR low group (p = 0.011) (Supplementary Table S1).

When analyzed contrariwise, the OS and BCSS rates were similar among the HER2+ patients with a low NLR irrespective if they had received adjuvant trastuzumab (Supplementary Fig. S1e–f, Table 4). On the contrary, among the patients with a high NLR, the OS was 73% in patients with adjuvant trastuzumab vs. 31% in those not receiving this therapy (p = 0.017) (Supplementary Fig. S1a, Table 4), and the corresponding BCSS rates were 87% vs. 42% (p = 0.017) (Supplementary Fig. S1b, Table 4). Thus, adjuvant trastuzumab conferred a survival advantage especially among those HER2+ patients with a high NLR at baseline. Similarly, among the HER2+ patients with a high MLR, BCSS was prolonged (p = 0.044) and there was also a trend towards improved OS (p = 0.064) among those who received adjuvant trastuzumab (Supplementary Fig. S1c–d, Table 4), whereas among the patients with a low MLR, there were no differences in survival irrespective whether or not they received adjuvant trastuzumab (Supplementary Fig. S1g–h, Table 4).

**Cox multivariate analyses**

In the Cox multivariate analyses, the significant prognostic factors for OS among the HER2+ patients were HR status and adjuvant trastuzumab (p ≤ 0.043); for BCSS these were nodal status, HR status and adjuvant trastuzumab (p ≤ 0.041) (Table 5). Among the patients treated with adjuvant trastuzumab (n = 43), none of the factors reached statistical significance (data not shown). Among the HER2+ patients treated without adjuvant trastuzumab (n = 64), HR status (p = 0.013, HR 0.38, 95% CI 0.18–0.82) and NLR (p = 0.046, HR 3.11, 95% CI 1.02–9.50) were significant prognostic factors for OS, and HR status also for BCSS (p = 0.023, HR 0.39, 95% CI 0.17–0.88). Table 5 shows the results of the COX multivariate survival analyses also among all the patients and in the HR+, HR− and HER2− subgroups.

**Discussion**

In this study, we found that the outcome of the HER2+ BC patients with a high NLR or MLR was poor if their adjuvant treatment did not include trastuzumab. Trastuzumab was especially beneficial for those HER2+ patients with a high baseline NLR or MLR, while the survival of the HER2+ patients with a low NLR or MLR was good irrespective if they received adjuvant trastuzumab. Both high NLR and MLR correlated with poor survival also in the whole patient material and in HR+ and HR− subgroups.

Based on the results emerging from the present study, we hypothesize that trastuzumab modulates the systemic inflammatory state of the host and overcomes the poor prognostic impact of high baseline NLR and MLR. Indeed, it has been shown in advanced HER2+ BC that after one cycle of trastuzumab emtansine the blood lymphocyte counts were elevated, resulting in a decreased NLR and improved outcome [19]. In another study, after one cycle of trastuzumab, the neutrophil count decreased among patients exhibiting a response to trastuzumab but increased among those who did not benefit from trastuzumab [20]. It is also known that at least some chemotherapeutic agents have immune-modulatory effects, e.g., paclitaxel may sensitize tumor cells to cytotoxic T-lymphocyte mediated cell death [21] which also plays a crucial role in trastuzumab’s mechanism of action. Thus, the synergistic effect of trastuzumab with chemotherapy, especially with taxanes, seems to be at least in part explained by the improvement in the anti-tumor immune response [22]. Since in the present study the patients received trastuzumab in combination with chemotherapy,
81% with taxane, it is not possible to analyse if the possible immune-modulatory effect is due to trastuzumab alone, chemotherapy or both.

The host’s inflammatory state also seems to influence on the efficacy of immuno-oncological (IO) treatments, e.g., programmed death-1/programmed death ligand-1 (PD-1/PDL-1).
PD-L1) inhibitors. In recent years, IO-treatments have shown remarkable efficacy in many cancer types but in BC only a small subset of patients obtain long-lasting responses [23]. It is important to understand the mechanisms behind treatment responses to expand the proportion of patients benefiting from these treatments. A high NLR has been reported to be a marker of poor prognosis also in cancer patients treated with PD-1/PD-L1 inhibitors [24]. Thus, trastuzumab’s possible ability to modulate the blood lymphocyte and neutrophil counts provides a rationale for combining trastuzumab with IO-treatments. In fact, there are ongoing clinical trials investigating the efficacy of these combination treatment strategies [23]. Furthermore, it would be important to understand the mechanisms behind the increased NLR/MLR as they may reveal new risk factors for poor outcome in BC. In many diseases, such as cancer, infections or chronic inflammatory diseases, a high NLR/MLR might reflect the state of host’s systemic inflammation before the illness, the immunological response mounted against the illness or some aspects of the illness itself. Interestingly, the new COVID-19-infection seems to be especially serious among patients with a high NLR [25] and more often severe also among patients with chronic inflammatory conditions. Here, NLR or MLR did not correlate with the standard prognostic factors, suggesting that in BC NLR and MLR are not a consequence of the aggressiveness or extent of the cancer itself but otherwise modulate tumor progression and treatment responses.

One recent retrospective study has compared the prognostic value of the NLR among HER2+ patients treated with or without adjuvant trastuzumab [16]. In contrast to our results, NLR was not prognostic among HER2+ patients treated without trastuzumab but showed prognostic value among the patients with 1-year adjuvant trastuzumab. The difference in the 3-year DFS rate was rather small, 95.3% vs. 90.5% for low and high NLR groups, respectively, with a rather short median follow-up time of 20 months [16]. In our study, with a long follow-up time (median 10.4 years), the prognostic impact of both NLR and MLR according to OS, BCSS and distant relapse rate was found among the HER2+ patients treated without adjuvant trastuzumab but not among those who did receive trastuzumab. Importantly, NLR remained as a significant prognostic factor for OS also in the COX multivariate analysis. There are several explanations for these contradicting results, e.g., there are differences in determining the optimal cut-off-point for NLR, in the timing of the pre-treatment blood samples, in the treatments received in addition to trastuzumab and in the length of trastuzumab treatment. Furthermore, there is no knowledge of the inflammatory state of the tumor microenvironment, e.g., TILs, tumor associated macrophages (TAMs) and

### Table 4 Survival analyses of the HER2+ patients treated without or with adjuvant trastuzumab

|                      | OS  | p value | HR   | 95% CI   | BCSS | p value | HR   | 95% CI   |
|----------------------|-----|---------|------|----------|------|---------|------|----------|
| HER2+ no adj trastuzumab n = 64 |     |         |      |          |      |         |      |          |
| NLR high             | 31% | 0.003   | 3.16 | 1.49–6.73| 42%  | 0.014   | 2.78 | 1.24–6.21|
| NLR low              | 71% |         | 74%  |          |      |         |      |          |
| MLR high             | 33% | 0.006   | 2.95 | 1.39–6.27| 44%  | 0.020   | 2.64 | 1.19–5.90|
| MLR low              | 70% |         | 73%  |          |      |         |      |          |
| HER2+ adj trastuzumab n = 43 |     |         |      |          |      |         |      |          |
| NLR high             | 73% | 0.947   | 0.96 | 0.28–3.29| 87%  | 0.360   | 0.48 | 0.10–2.31|
| NLR low              | 75% |         | 75%  |          |      |         |      |          |
| MLR high             | 67% | 0.374   | 1.72 | 0.52–5.63| 78%  | 0.850   | 1.14 | 0.30–4.24|
| MLR low              | 80% |         | 80%  |          |      |         |      |          |
| HER2+ NLR high n = 41 |     |         |      |          |      |         |      |          |
| Adj trastuzumab      | 73% | 0.017   | 0.27 | 0.09–0.79| 87%  | 0.017   | 0.16 | 0.04–0.72|
| No adj trastuzumab   | 31% |         | 42%  |          |      |         |      |          |
| HER2+ NLR low n = 66  |     |         |      |          |      |         |      |          |
| Adj trastuzumab      | 75% | 0.859   | 0.92 | 0.35–2.40| 75%  | 0.873   | 0.92 | 0.35–2.43|
| No adj trastuzumab   | 71% |         | 74%  |          |      |         |      |          |
| HER2+ MLR high n = 45 |     |         |      |          |      |         |      |          |
| Adj trastuzumab      | 67% | 0.064   | 0.41 | 0.16–1.05| 78%  | 0.044   | 0.32 | 0.11–0.97|
| No adj trastuzumab   | 33% |         | 44%  |          |      |         |      |          |
| HER2+ MLR low n = 62  |     |         |      |          |      |         |      |          |
| Adj trastuzumab      | 80% | 0.391   | 0.63 | 0.22–1.81| 80%  | 0.512   | 0.70 | 0.24–2.04|
| No adj trastuzumab   | 70% |         | 73%  |          |      |         |      |          |

Adj adjuvant, OS overall survival, HR hazard ratio, CI confidence interval, BCSS breast cancer specific survival, NLR neutrophil-to-lymphocyte ratio, MLR monocyte-to-lymphocyte ratio.
NK-cells, all of which probably exert an influence on the response to trastuzumab [6].

In line with previous studies [9], a high NLR correlated here with poor survival among the HR− patients, but also in the HR+ subgroup. A long follow-up period for survival and BC specific outcomes may be especially important in HR+ BC in which the recurrences often occur quite late. Furthermore, we found a correlation between MLR and survival among the HER2+, HR+ and HR− patients suggesting that also monocytes have an important role in BC progression. Instead, in the HER2− and triple-negative subgroups, we did not find statistically significant correlations between NLR or MLR and survival, but among the HER2− patients the number of events was rather small, and the triple-negative subgroup was too small for reliable statistical analyses.

The strengths of our study include its unique patient material in which approximately half of the HER2+ patients had received adjuvant trastuzumab. Two other strengths are the long follow-up period and reliable patient records. This study has also limitations; first, since this is a retrospective observational study, the causal relationships between the investigated factors remain hypothetical.
Second, chemotherapy was administered more often to patients who received adjuvant trastuzumab compared to those who did not, which must be considered in the interpretation of the results since also chemotherapy may modulate inflammatory responses as discussed above. Third, the number of patients in some of the subgroup analyses was small. Thus, the results will need to be confirmed in larger randomized studies.

Conclusions

This study detected a prognostic impact of both NLR and MLR, i.e., two inexpensive and readily available inflammatory markers, in BC, including the HER2+ subgroup. Our finding that also a high MLR correlates with poor survival strengthens the idea that in addition to neutrophils and lymphocytes, monocytes also play an important role in BC progression and treatment responses. Interestingly, the prognostic impact of NLR and MLR was present only among those HER2+ patients who had not received adjuvant trastuzumab, and adjuvant trastuzumab was beneficial especially for those patients with a high NLR or MLR before the initiation of adjuvant treatment. These results suggest that trastuzumab, at least together with chemotherapy, may improve the inflammatory state of the host and overcome the poor prognostic impact of high baseline NLR and MLR, which could also provide a rationale for combining trastuzumab with IO-treatments. More studies are needed to clarify the role of inflammatory cells in the regulation of tumor progression and treatment responses to further improve BC treatments and outcome.

Acknowledgements We thank Tuomas Selander (Science Service Center, Kuopio University Hospital, Finland) for assistance with the statistical analyses, and Jarkko Romppanen (Eastern Finland Laboratory Centre, Kuopio, Finland) for reporting the methodology of laboratory analyses. We also thank Ewen MacDonald for English language editing.

Author contributions Study design was performed by ST and PA, and collection and analysis of the data by ST. All authors commented on the manuscript, and read and approved the final manuscript.

Funding Open access funding provided by University of Eastern Finland (UEF) including Kuopio University Hospital. This study was supported by the Finnish Society for Oncology, Ida Montini Foundation and the Special Government Funding (EVO/VTR) of Kuopio University Hospital under Grant 1V315, 5654132. The funders did not participate in the design, conduction or data interpretation of this study.

Data availability The datasets generated and/or analyzed during the current study are not publicly available due to the fact that they contain information that could compromise research participant privacy but may be available from the corresponding author on reasonable request and with required permissions.

Compliance with ethical standards

Conflict of interest Satu Tiainen has received financial support for attending conferences and honoraria for speaking at symposia and participating in advisory boards from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Novartis, Pfizer, Roche and Takeda. None of the financial support regarded this study. Päivi Auvinen reports funding from Roche for attending ESMO Breast Cancer Congress 2019. All other authors declare that they have no conflict of interest.

Ethical approval All procedures performed in this study were in accordance with the ethical standards of The Ethics Committee of the University of Eastern Finland (February 24, 2009, 19//2009), and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent Informed consent was not required since this retrospective study was conducted on already existing material, and acquiring informed consent from all the patients would not have been possible.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Fridman WH, Zitvogel L, Sautes-Fridman C et al (2017) The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14:717–734
2. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674
3. Nemeth T, Sperandio M, Mocsai A (2010) Neutrophils as emerging therapeutic targets. Nat Rev Drug Discov 19:253–275
4. Coffelt SB, Kersten K, Doornebal CW et al (2015) IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522:345–348
5. Augier S, Ciucci T, Luci C et al (2010) Inflammatory blood monocytes contribute to tumor development and represent a privileged target to improve host immunosurveillance. J Immunol 185:7165–7173
6. Andre F, Dieci MV, Dubsky P et al (2013) Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res 19:28–33
7. Corbeau I, Jacot W, Guiu S (2020) Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: a systematic review. Cancers (Basel) 12(4):958. https://doi.org/10.3390/cancers12040958
8. Guo W, Lu X, Liu Q et al (2019) Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med 8:4135–4148

9. Ethier JL, Desautels D, Templeton A et al (2017) Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res 19(1):2. https://doi.org/10.1186/s13058-016-0794-1

10. Cho U, Park HS, Im SY et al (2018) Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. PLoS One 13:e0200936. https://doi.org/10.1371/journal.pone.0200936

11. Losada B, Guerra JA, Malon D et al (2019) Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients. Clin Transl Oncol 21:855–863

12. Madarnas Y, Trudeau M, Franek JA et al (2008) Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 34:539–557

13. Loi S, Michiels S, Salgado R et al (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25:1544–1550

14. Ulas A, Avci N, Kos T et al (2015) Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab? J BUON 20:714–722

15. Hong J, Chen X, Gao W et al (2019) A high absolute lymphocyte count predicts a poor prognosis in HER-2-positive breast cancer patients treated with trastuzumab. Cancer Manag Res 11:3371–3379

16. Ding N, Huang J, Li N et al (2020) Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy. BMC Cancer 20:235. https://doi.org/10.1186/s12885-020-06750-3

17. Auvinen P, Tammi R, Kosma VM et al (2013) Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. Int J Cancer 132:531–539

18. Sobin LH, Wittekind C (2002) TNM classification of malignant tumours, 6th edn. UICC, New York

19. Imamura M, Morimoto T, Egawa C et al (2019) Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine. Sci Rep 9:1811. https://doi.org/10.1038/s41598-018-37633-0

20. Triulzi T, Regondi V, De Cecco L et al (2018) Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. Br J Cancer 119:1487–1494

21. Ramakrishnan R, Gabrilovich DI (2011) Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. Cancer Immunol Immunother 60:419–423

22. Di Modica M, Sfondrini L, Regondi V et al (2016) Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. Oncotarget 7:255–265

23. Esteva FJ, Hubbard-Lucey VM, Tang J et al (2019) Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol 20:e175–e186. https://doi.org/10.1016/S1470-2045(19)30026-9

24. Iivanainen S, Ahvonen J, Knuuttila A et al (2019) Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. ESMO Open 4:e000531. https://doi.org/10.1136/esmoopen-2019-000531

25. Yang AP, Liu JP, Tao WQ et al (2020) The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol 84:106504. https://doi.org/10.1016/j.intimm.2020.106504

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.